Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?

被引:17
|
作者
Kasper, B [1 ]
Harter, C [1 ]
Meissner, J [1 ]
Bellos, F [1 ]
Krasniqi, F [1 ]
Ho, AD [1 ]
Egerer, G [1 ]
机构
[1] Univ Heidelberg, Dept Internal Med 5, D-69115 Heidelberg, Germany
关键词
ifosfamide-induced encephalopathy; Ewing sarcoma; high-dose chemotherapy (HDCT); peripheral blood stem cell transplantation (PBSCT);
D O I
10.1007/s00520-003-0573-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report about a case of advanced Ewing sarcoma in a 30-year-old woman. Initial treatment was started according to the Euro-Ewing 99 protocol. During the initial therapy, an ifosfamide-induced encephalopathy occurred as status epilepticus. Because of cerebral toxicity, the following chemotherapies went without ifosfamide. During final radiotherapy multiple lung metastasis were diagnosed. After two cycles of chemotherapy with cyclophosphamide and topotecan (no response), left thoracotomy, and palliative pneumectomy, the patient was transferred to our ward for further treatment. Undergoing two cycles of chemotherapy with ifosfamide 4 g/m(2) intravenously for 3 consecutive days followed by high-dose chemotherapy (HDCT) according to the ICE-regimen ( ifosfamide 2 g/m(2), carboplatin 200 mg/m(2), and etoposide 2 x 100 mg/m(2) intravenously for 6 consecutive days), and peripheral blood stem cell transplantation (PBSCT), complete remission was achieved. Under preventive therapy with methylene blue, thiamin, and glucose 5% infusions, no encephalopathy occurred.
引用
收藏
页码:205 / 207
页数:3
相关论文
共 50 条
  • [21] IFOSFAMIDE-INDUCED NEPHROTOXICITY
    ROSSI, R
    RATH, B
    ULLRICH, K
    EHRICH, JHH
    MONATSSCHRIFT KINDERHEILKUNDE, 1993, 141 (07) : 594 - 601
  • [22] Ifosfamide-induced encephalopathy: Brand-name (HOLOXAN®) vs generic formulation (IFOSFAMIDE EG®)
    Chambord, Jeremy
    Henny, Fabien
    Salleron, Julia
    Hombourger, Benoit
    Lider, Pauline
    Vigneron, Jean
    Demore, Beatrice
    Vallance, Catherine
    Rios, Maria
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (03) : 372 - 380
  • [23] Ifosfamide-induced encephalopathy: implication of CYP polymorphisms and metabolism enantioselectivity
    Duflot, T.
    Massy, N.
    Bellien, J.
    Verstuyft, C.
    Marie-Cardine, A.
    Vannier, J. P.
    Lamoureux, F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 85 - 85
  • [24] Effectiveness of Exogenous Albumin Administration for the Prevention of Ifosfamide-Induced Encephalopathy
    Kettle, Jacob K.
    Grauer, Dennis
    Folker, Tanya L.
    O'Neal, Nyla
    Henry, David W.
    Williams, Casey B.
    PHARMACOTHERAPY, 2010, 30 (08): : 812 - 817
  • [25] Ifosfamide-induced Encephalopathy With Rapid Response to Thiamine: A Pediatric Case
    Mungen, Eren
    Bajin, Inci Yaman
    Oz, Sibel
    Gunbey, Ceren
    Anlar, Banu
    Aydin, Burca
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2022, 44 (07) : 402 - 404
  • [26] Comparative study of the acute nephrotoxicity from standard dose cisplatin ± ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide
    Hartmann, JT
    Fels, LM
    Franzke, A
    Knop, S
    Renn, M
    Maess, B
    Panagiotou, P
    Lampe, H
    Kanz, L
    Stolte, H
    Bokemeyer, C
    ANTICANCER RESEARCH, 2000, 20 (5C) : 3767 - 3773
  • [27] Recurrent ifosfamide-induced hyponatraemia
    Kirch, C
    Gachot, B
    Germann, N
    Blot, F
    Nitenberg, G
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (14) : 2438 - 2439
  • [28] IFOSFAMIDE-INDUCED HYPERPIGMENTATION - REPLY
    TERESI, ME
    MURRY, DJ
    CORNELIUS, AS
    CANCER, 1994, 73 (01) : 241 - 241
  • [29] Ifosfamide-Induced Tubuler Dysfunction
    Tokuc, G.
    Eker, N.
    Senay, E.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S171 - S171
  • [30] IFOSFAMIDE-INDUCED FANCONI SYNDROME
    GARCIA, AA
    ANNALS OF PHARMACOTHERAPY, 1995, 29 (06) : 590 - 591